TickerTalks
Browse all tickers →
TickerTalks›$ZNTL
ZNZNTL

Zentalis Pharmaceuticals, Inc.

$ZNTL·$310M·Biotechnology·Healthcare
$4.46+2.4%YTD+222.6%1Y+266.0%
Mentions · last 7 days
2026-06-25: 2 posts2026-06-26: 0 posts2026-06-27: 0 posts2026-06-28: 0 posts2026-06-29: 11 posts2026-06-30: 200 posts2026-07-01: 0 posts213
Price updated 37m ago·X counts updated 23h ago
ZNZNTL
$ZNTLZentalis Pharmaceuticals, Inc.
$4.46+2.41%213 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ZNTL, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeCooling offAI verdict · as of 2026-07-02

Catching its breath after a run — could pick back up or fade from here.

Precision-oncology biotech up 222% YTD on Azenosertib ovarian-cancer data — the ASCO readout was real, but today's -10% day is the first meaningful cooling.

Zentalis Pharmaceuticals develops precision oncology therapeutics with a specific focus on Azenosertib — a WEE1 inhibitor being tested in platinum-resistant ovarian cancer and other solid tumors. It's up 222% year-to-date on the specific data-readout momentum.

  • The clinical data is legitimate: Phase 1b MUIR Trial data presented at ASCO 2026 showed encouraging clinical activity and a manageable safety profile of Azenosertib plus paclitaxel in platinum-resistant ovarian cancer — a specific data event that supported the initial rerating.
  • The business is fully clinical stage: Q1 revenue was essentially zero with an operating margin of zero (on the tiny base) and free cash flow of -$33M — this is a company living on capital raises and grants rather than commercial revenue, and burn rate is meaningful relative to market cap.
  • Governance is being strengthened: five director grants of 57,100 shares each on June 16 plus new commercial leadership appointments (Sarah Kelly as SVP of Commercial Strategy on May 27) reflect specific build-out for potential commercialization — but commercial hires ahead of actual approval is a specific spend signal.
  • The valuation reflects the readout risk: at a $300M market cap with essentially zero revenue and $-33M quarterly FCF, ZNTL is priced entirely on Azenosertib's Phase 2/3 progression — the multiple assumes a specific data-driven inflection.

The trajectory is cooling with a -10.2% day at 55% of the 52-week range. What restarts the accelerating call is August 5 Q2 earnings showing cash runway extension plus a specific new Phase 2/3 study announcement; what confirms cooling into breaking-down is a specific safety signal in a follow-on readout, another dilutive raise at low prices, or a competitor (Merus, Repare) landing an ahead-of-schedule WEE1 data readout.

What to watch: August 5 Q2 earnings — cash runway update, any new Phase 2/3 study announcement, and specific Azenosertib data pipeline. A cash-runway extension plus new study announcement restarts the run; a safety signal or dilutive raise confirms cooling into breaking-down.

On the calendar: 2026-08-05 — Q2 earnings

no sentiment

Read the AI verdict + X sentiment for $ZNTL

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ZNTL.

Biotechnology · Healthcare

GLP-1 pipeline competition is the dominant structural driver — the ADA conference crystallized oral formulations, dual agonists, and differentiated mechanisms competing for a potential $150B obesity market by 2030. QURE's FDA accelerated approval for AMT-130 (Huntington's disease) this week confirms gene therapy regulatory momentum is still flowing capital to non-GLP-1 precision medicine.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+49.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-65.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-40.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-53.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 12, 2026$-0.50$-0.49-2.0%
Q4 2025Mar 26, 2026$-0.49$-0.41-19.5%
Q3 2025Nov 10, 2025$-0.37$-0.49+24.5%
Q2 2025Aug 6, 2025$-0.37$-0.56+33.9%
Next earningsWed, Aug 5·consensus EPS $-0.45

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.50$-33.0M
Q4 FY25$0-100.0%——$-0.49$-30.9M
Q3 FY25$0———$-0.37$-27.0M
Q2 FY25$0———$-0.37$-34.7M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.1M$1.6M – $2.4M-$1.94-$2.22 – -$1.608
FY27$24.1M$17.6M – $27.5M-$1.68-$2.27 – -$1.107
FY28$77.0M$77.0M – $77.0M-$1.53-$2.45 – -$0.577
FY29$168.9M$123.3M – $192.7M-$0.74-$0.87 – -$0.483
FY30$272.2M$198.7M – $310.6M$0.04$0.02 – $0.046

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.55%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+10.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+67.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 48.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.985-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellFeb 10Vincent VultaggioPAO and PFO6.9K sh$17KSellFeb 9Ingmar BrunsChief Medical Officer335 sh$802SellFeb 9Vincent VultaggioPAO and PFO3.4K sh$8KSellFeb 9Eastland Julia MarieCEO889 sh$2KSellFeb 6Ingmar BrunsChief Medical Officer3.0K sh$7KSellFeb 6Vincent VultaggioPAO and PFO30.0K sh$73KSellFeb 6Eastland Julia MarieCEO7.9K sh$19KSellFeb 3Vincent VultaggioPAO and PFO556 sh$1KSellFeb 2Vincent VultaggioPAO and PFO2.5K sh$6K
+ 10 other (10 awards) in window

See when $ZNTL insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·31d agoZentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategyglobenewswire.com·36d agoZentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026globenewswire.com·42d agoZentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026globenewswire.com·42d agoZentalis Pharmaceuticals to Participate in Upcoming Investor Conferencesglobenewswire.com·50d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$IBRX$MRNA$SLS$ABVX$AURA$ABCL$RVMD$RLAY
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport